Using Watson, the Sugar.IQ app gives people with diabetes personalised insights to help them make more informed decisions to better manage glucose levels and keep them in the target range.
The app works exclusively with the Guardian™ Connect Continuous Glucose Monitoring (CGM) system and continually analyses glucose, insulin, food and other data from past and present to give users a better understanding of how lifestyle choices, medications and multiple daily injections impact diabetes management.
“Data-driven technologies like AI, machine learning and analytics are changing the way people manage their health today, and the launch of the Sugar.IQ app with Watson is an indication of where the future of disease management is headed,” said Vice President and Chief Health Officer at IBM Watson Health, Dr Kyu Rhee.
“Through IBM Watson Health’s partnership with Medtronic, we’re bringing the power of AI to the everyday lives of people with diabetes, with the goal of lessening the burden of disease,” continued Dr Rhee.
According to a Stanford study, the average patient with diabetes has to make more than 180 decisions daily based on careful monitoring of their glucose, nutritional intake and activity level. Medtronic believes their Sugar.IQ diabetes assistant app will alleviate a lot of this burdensome daily routine.
During the recent American Diabetes Association’s (ADA) 78th Scientific Sessions, Medtronic presented new data demonstrating the utility of Sugar.IQ in a real-world setting. The study found that people with diabetes using the Sugar.IQ app spent 36 more minutes per day in healthy glucose range compared to before they used the app. This included 30 minutes less time in hyperglycemia (>180 mg/dL) and six minutes less time in hypoglycemia (<70 mg/dL). This represents more than nine additional days in a year that a person with diabetes is spending in a healthy glucose range.